Published in Am J Clin Oncol on October 01, 2003
AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of Task Group 137. Med Phys (2009) 2.62
Robotic assistance for ultrasound-guided prostate brachytherapy. Med Image Anal (2008) 1.32
Ultrasound-fluoroscopy registration for prostate brachytherapy dosimetry. Med Image Anal (2012) 0.88
On the need to compensate for edema-induced dose reductions in preplanned (131)Cs prostate brachytherapy. Int J Radiat Oncol Biol Phys (2007) 0.77
The impact of prostate edema on cell survival and tumor control after permanent interstitial brachytherapy for early stage prostate cancers. Phys Med Biol (2011) 0.77
Prostate implant reconstruction from C-arm images with motion-compensated tomosynthesis. Med Phys (2011) 0.76
Quantification of edematic effects in prostate brachytherapy interventions. Med Image Comput Comput Assist Interv (2008) 0.75
Preimplant factors affecting postimplant CT-determined prostate volume and the CT/TRUS volume ratio after transperineal interstitial prostate brachytherapy with 125I free seeds. Radiat Oncol (2010) 0.75
Intraoperative Registered Ultrasound and Fluoroscopy (iRUF) for dose calculation during prostate brachytherapy: Improved accuracy compared to standard ultrasound-based dosimetry. Radiother Oncol (2017) 0.75
Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res (2003) 7.86
Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci U S A (2003) 7.44
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol (2004) 4.77
Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med (2010) 4.11
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys (2008) 3.78
Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys (2004) 2.84
Results of chest wall resection and reconstruction with and without rigid prosthesis. Ann Thorac Surg (2006) 2.77
Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys (2005) 2.75
Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys (2006) 2.69
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69
Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys (2003) 2.58
Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology (2010) 2.57
Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol (2007) 2.54
Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol (2012) 2.45
Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer (2010) 2.42
American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol (2007) 2.41
Fluoroscopically guided interventional procedures: a review of radiation effects on patients' skin and hair. Radiology (2010) 2.36
A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol (2013) 2.33
Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov (2013) 2.15
High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06
American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy (2012) 2.03
Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol (2002) 1.99
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol (2006) 1.97
The paradox of multidisciplinary care. Int J Radiat Oncol Biol Phys (2012) 1.97
Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.91
Intensity-modulated radiation therapy: supportive data for prostate cancer. Semin Radiat Oncol (2008) 1.91
PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys (2005) 1.83
Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. Eur Urol (2011) 1.81
Correlation of osteoradionecrosis and dental events with dosimetric parameters in intensity-modulated radiation therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2011) 1.80
Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys (2005) 1.77
Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys (2010) 1.77
The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg (2006) 1.70
Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys (2007) 1.69
Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology (2006) 1.69
Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2012) 1.68
Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2002) 1.67
Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. Int J Radiat Oncol Biol Phys (2006) 1.62
Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience. Int J Radiat Oncol Biol Phys (2009) 1.58
Adjuvant radiation for stage II-B soft tissue sarcoma of the extremity. J Clin Oncol (2002) 1.58
Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.56
Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys (2007) 1.54
Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol (2003) 1.51
Single-fraction intraoperative radiotherapy for breast cancer: early cosmetic results. Int J Radiat Oncol Biol Phys (2007) 1.50
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer (2006) 1.49
Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys (2008) 1.46
Locally advanced prostate cancer: a population-based study of treatment patterns. BJU Int (2011) 1.46
American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy (2012) 1.45
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials. Gynecol Oncol (2007) 1.44
Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer. Cancer J (2006) 1.42
Less-restrictive, patient-specific radiation safety precautions can be safely prescribed after permanent seed implantation. Brachytherapy (2009) 1.42
A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2006) 1.39
How one defines intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys (2003) 1.39
Point: There is a need for supplemental XRT with brachytherapy in the treatment of intermediate-risk prostate cancer patients. Brachytherapy (2013) 1.38
On the question of defining misadministration in brachytherapy: counterpoint. Brachytherapy (2002) 1.38
Intensity-modulated radiotherapy for soft tissue sarcoma of the thigh. Int J Radiat Oncol Biol Phys (2004) 1.37
Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology (2002) 1.37
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology (2008) 1.32
Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.32
Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys (2007) 1.31
Microvascular function regulates intestinal crypt response to radiation. Cancer Res (2003) 1.30
Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting--the MSKCC experience. Int J Radiat Oncol Biol Phys (2006) 1.29
American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin (2014) 1.29
Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.28
Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol (2006) 1.28
Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol (2003) 1.27
Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys (2006) 1.27
Hypofractionated dose-painting intensity modulated radiation therapy with chemotherapy for nasopharyngeal carcinoma: a prospective trial. Int J Radiat Oncol Biol Phys (2010) 1.25
Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer? Int J Radiat Oncol Biol Phys (2002) 1.21
Dose-rate effects in external beam radiotherapy redux. Radiother Oncol (2010) 1.20
Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.19
Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes. Int J Radiat Oncol Biol Phys (2011) 1.17
Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities. Int J Radiat Oncol Biol Phys (2008) 1.15
Towards integrating functional imaging in the treatment of prostate cancer with radiation: the registration of the MR spectroscopy imaging to ultrasound/CT images and its implementation in treatment planning. Int J Radiat Oncol Biol Phys (2002) 1.14
Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol (2004) 1.13
Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol (2011) 1.13
Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int J Radiat Oncol Biol Phys (2010) 1.13
Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol (2003) 1.12
Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.12
Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys (2008) 1.11
Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys (2003) 1.11
Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest (2006) 1.11
Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer. BJU Int (2014) 1.10
Automated finite-element analysis for deformable registration of prostate images. IEEE Trans Med Imaging (2007) 1.09
Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy (2010) 1.09
Intensity-modulated radiotherapy. Cancer J (2002) 1.07
Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator: pilot data and comparison to laparotomy. Gynecol Oncol (2003) 1.07